GlobeNewswire

OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion
09/11/2026
14% year-over-year revenue growth in the quarter highlights effectiveness of return-to-growth strategy GAAP gross margin improved by over 170 bps vs. prior year to 45.2% Received initial orders of Colli-Pee®•Dx and [...]
Rani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate Update
09/11/2026
~ Accepted into the U.S. FDA’s Emerging Technology Program (ETP), enabling early FDA engagement to support development of the RaniPill ® platform technology ~ ~ Enrollment continues in RT-114 Phase 1a expansion cohort; [...]
Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
09/11/2026
Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027 Enrollment ongoing in Phase 2 CIPheR trial of MZE782 in PKU; topline data expected in 2027 Phase 2 trial of [...]
Senseonics Holdings, Inc. Reports Third Quarter 2026 Financial Results
09/11/2026
Generated third quarter revenue of $19.6 million, an increase of approximately 140% year-over-year Raised full-year 2026 revenue guidance to $68 million to $70 million from $62 million to $66 million, representing year- [...]
Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update
09/11/2026
First patient dosed in Phase 1b of DUET study evaluating SZN-8141 in patients with diabetic macular edema DUET Phase 2a enrollment to be expanded from approximately 60 to 150 patients to enable a more robust evaluation [...]
Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates
09/11/2026
DENALI Part 1b survival data strengthen azenosertib's position as the potential first-in-class oral, non-chemotherapy, non-ADC therapy in pivotal development for Cyclin E1-positive PROC DENALI Part 2c enrollment [...]
MapLight Therapeutics to Participate in Upcoming Investor Conference
09/11/2026
SAN FRANCISCO and BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conference: Event : [...]
Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
09/11/2026
Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the underlying cause of FA Submission follows FDA alignment on key elements of the [...]
Stryker announces intention to nominate Jim Davis to board of directors
09/11/2026
Portage, MI, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Stryker announces intention to nominate Jim Davis to board of directors Stryker (NYSE:SYK) announced that its board of directors has nominated Jim Davis for election to the [...]
PetMeds Announces Strategic Partnership with Pet Supermarket to Expand Pharmacy Offering Across Retail and Digital Channels
09/11/2026
DELRAY BEACH, Fla., Nov. 09, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced a new partnership with Pet Supermarket to offer pet prescription [...]
Apollomics Reports First-Half 2026 Financial Results
09/11/2026
Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. FOSTER CITY, Calif., Nov. 09, 2026 ( [...]
ImageneBio Reports Third Quarter 2026 Financial Results
09/11/2026
SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the quarter ended September 30, 2026, and provided a company update. Company [...]
Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
09/11/2026
Initiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials actively recruiting Positive meeting with the FDA on the non-IPF ILD-related chronic cough [...]
Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
09/11/2026
EVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with EVERLAST-A EVERLAST-A responses continued to deepen to 71% PASI 100 at Week 28, 6 months after last [...]
Globus Medical to Participate in Jefferies Global Healthcare Conference
09/11/2026
AUDUBON, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it is scheduled to participate in the Jefferies Global Healthcare [...]
Harrow Announces Third Quarter 2026 Financial Results
09/11/2026
Third Quarter 2026 and Selected Highlights: Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year Branded revenue of $83.5 million, up 62% year over year and approximately 84% of [...]
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2026
09/11/2026
Awarded $15 Million Procurement Contract from Canadian Department of National Defence for Oral TPOXX in October Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- SIGA [...]
Xenon Reports Q3 2026 Financial Results and Provides Business Update
09/11/2026
New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026 Expanding potential opportunity in epilepsy through ongoing Phase 3 X-TOLE3 and X-ACKT studies [...]
POLYRIZON ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS PLAN
09/11/2026
TEL AVIV, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum